A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved ... The data with the CRISPR/Cas9 drug CTX001 is still very early-stage, coming from just seven thalassaemia ...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can ... to begin an early stage trial of CTX001, a gene therapy derived from ...

To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

The company has also established strategic partnerships to bolster its research and development efforts, including a collaboration with Vertex Pharmaceuticals. CRISPR Therapeutics AG, with its ...

Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should ...

To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the fourth quarter, HoldingsChannel.com reports.The firm owned 8,827 shares ...